This edition has been updated to include new standards in the treatment of malignancies and hematologic disorders, mechanisms of action of new therapeutic agents, and the current use of molecular prognostic factors.
... EcoR1 Capital, LLC, EcoR1 CTOS Adboard 2022- not paid Curis VISTA AdBoard 8/2022 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Polaris Board Member- nonpaid Patents planned, issued or ...
This website uses cookies and collects data for optimal performance. Your continued use signifies agreement to our Privacy Policy.
